Ardelyx (ARDX) reported $407M in revenue for fiscal 2025, +22.1% year on year. That ranks #2341 by revenue among 2853 SEC filers and #228 in Healthcare. It posted a net loss of −$62.0M for the same year. Revenue has grown 39.4% a year on average since 2012 ($5.4M then). The fiscal 2025 balance sheet shows $502M in total assets, $68.0M in cash and $203M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $407M | +22.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $4.7M | +118.6% | FY20192019-12-31 |
| Operating incomeOperatingIncomeLoss | −$41.0M | −$13.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$62.0M | −$23.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$42.5M | +$2.3M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.5M | +47.6% | FY20252025-12-31 |
| Total assetsAssets | $502M | +15.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $167M | −3.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $68.0M | +4.7% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $203M | +34.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $94.5M | −$37.6M | Open → |
| Q2 20262026-06-30 | $121M | −$16.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ardelyx, Inc.
- Ticker
- ARDX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001437402
Filings
- 10-QAug 6, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
| ArdelyxARDX | $407M | −$62.0M |
| Immunocore HoldingsIMCR | $400M | −$35.5M |
| Krystal BiotechKRYS | $389M | $205M |
| Sinovac BiotechSVA | $386M | −$199M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ardelyx — Key figures |url=https://companiesranked.com/en/company/ardelyx |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ardelyx — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ardelyxBibTeX
@misc{companiesranked-en-company-ardelyx-2026,
author = {{CompaniesRanked}},
title = {{Ardelyx — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ardelyx}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001437402-26-000013 · February 19, 2026
{{cite web |title=Ardelyx — Key figures — 10-K (0001437402-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1437402/000143740226000013/ardx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.